Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
Sweden
/
Pharmaceuticals & Biotech
/
Swedish Orphan Biovitrum
Create a narrative
Swedish Orphan Biovitrum Community
OM:SOBI Community
1
Narratives
written by author
0
Comments
on narratives written by author
14
Fair Values set
on narratives written by author
Community Investing Ideas
Swedish Orphan Biovitrum
Popular
Undervalued
Overvalued
Swedish Orphan Biovitrum
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Altuvoct Adoption And Gamifant Launches Will Unlock European Opportunities
Key Takeaways Successful Altuvoct launch in Europe and expanding regulatory approvals for Aspaveli and Gamifant could significantly boost revenue through market share growth and new entries. Strategic operational efficiency, cost management, and increased Beyfortus royalties are expected to enhance margins and stabilize earnings.
View narrative
SEK 341.18
FV
19.6% undervalued
intrinsic discount
10.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
14 days ago
author updated this narrative